FDA Investigator Lindsey S Fleischman
Lindsey S Fleischman has inspections in 4 countries as of 14 Jun 2023. Lindsey S Fleischman has collaborated with a combined 1060 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
6
Last Inspection Date:
14 Jun 2023
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America,
China,
Japan,
Italy
Co-Investigator(s):
Anitha P Govada,
Anitha Palamakula Govada,
Brittany D Terhar,
Bruce H Mccullough,
Carla A Norris,
Charles L Zhou,
Chelsea J Falkowski,
Chen Sun, PhD,
Cheryl A Clausen,
Chikako Torgioe,
Christina A Miller,
Christopher D Leach,
Constantin Y Philopoulos,
Cynthia Jim, CSO,
Darren S Morgan,
Deborah A Greco,
Debra I Love,
Denarvis C Mendenhall,
Dennis Cantellops Paite,
Donald W Myrick,
Dr. Barbara D Paul, PhD,
Dr. Jun Liu, PhD,
Emily J Orban,
Jacek Cieslak, PhD,
Junho Pak,
Kejun Cheng,
Kelley L Clark,
Kham Phommachanh,
Kristy A Zielny,
Leslie A Paul,
Lindsey M Schwierjohann,
Lucas B Leake,
Madushini Dharmasena, PhD,
Martha Sullivan Myricj,
Martha Sullivan Myrick,
Michael Shanks, MS,
Michael Y Philopoulos,
Nibin Varghese, MS,
Nicholas F Lyons,
Norman K Starks,
Patrick C Klotzbuecher,
Ramesh Potla, PhD,
Roger F Zabinski,
Rohn R Robertson,
Russell K Riley,
Scott R Nichols, PhD,
Shelby N Marler,
Simone E Pitts,
Susan M Jackson,
Susan P Bruederle,
Susant Hadman,
Thuy T Nguyen, LCDR,
Tonnie L Carter,
Tracey Asinjen Wiersma,
William D Sherman,
Zhong Li, PhD
Lindsey S Fleischman's Documents
Publish Date | Document Type | Title |
---|---|---|
December, 2022 | FDA 483 | Kyowa Kirin Co., Ltd. - Form 483, 2022-12-14 |
February, 2022 | EIR | PQ Corporation - EIR, 2022-02-22 |
February, 2023 | EIR | NerPharMa S.r.l. - EIR, 2023-02-20 |
October, 2019 | FDA 483 Response | L. Perrigo Company - Form 483R, 2019-11-07 |
October, 2019 | EIR | L. Perrigo Company - EIR, 2019-10-22 |
February, 2022 | FDA 483 | PQ Corporation - Form 483, 2022-02-22 |
October, 2019 | FDA 483 | L. Perrigo Company - Form 483, 2019-10-22 |
February, 2023 | FDA 483 | NerPharMa S.r.l. - Form 483, 2023-02-20 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more